bcl-2 inhibitor abbv-453
Generic: Bcl-2 Inhibitor ABBV-453
bcl-2 inhibitor abbv-453: 1 clinical trial tracked.
bcl-2 inhibitor abbv-453 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about bcl-2 inhibitor abbv-453, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trials (1)
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma
Primary endpoint: Dose-Limiting Toxicities (DLT)s of ABBV-453
InterventionalRandomizedopen199 targetStarted 2025-07Completion 2030-1248 sites · Australia, Belgium, France, Germany…AbbVie